Business Wire

bit.bio introduces first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease modelling and drug discovery

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announces the launch of the first offering from its new product range - ioCRISPR-Ready Cells™. This ...
Business Wire

bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis ...

A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...
WOOD-TV

bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.
News Medical

bit.bio launches new custom disease model cells offering, advancing disease research & drug discovery

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type TM cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild ...